The molecular reach of antibodies crucially underpins their viral neutralisation capacity

Anna Huhn, Daniel A. Nissley, Daniel B. Wilson, Mikhail A. Kutuzov, Robert F. Donat, Tiong Kit Tan, Ying Zhang, Michael I. Barton, Chang Liu, Wanwisa Dejnirattisai, Piyada Supasa, Juthathip Mongkolsapaya, Alain Townsend, William James, Gavin Screaton, P. Anton van der Merwe, Charlotte M. Deane, Samuel A. Isaacson, Omer DushekNature Communications 2025 · DOI

Abstract

Key functions of antibodies, such as viral neutralisation, depend on high-affinity binding. However, viral neutralisation poorly correlates with antigen affinity for reasons that have been unclear. Here, we use a new mechanistic model of bivalent binding to study >45 patient-isolated IgG1 antibodies interacting with SARS-CoV-2 RBD surfaces. The model provides the standard monovalent affinity/kinetics and new bivalent parameters, including the molecular reach: the maximum antigen separation enabling bivalent binding. We find large variations in these parameters across antibodies, including reach variations (22-46 nm) that exceed the physical antibody size (~15 nm). By using antigens of different physical sizes, we show that these large molecular reaches are the result of both the antibody and antigen sizes. Although viral neutralisation correlates poorly with affinity, a striking correlation is observed with molecular reach. Indeed, the molecular reach explains differences in neutralisation for antibodies binding with the same affinity to the same RBD-epitope. Thus, antibodies within an isotype class binding the same antigen can display differences in molecular reach, substantially modulating their binding and functional properties.

Introduction: The Affinity-Neutralization Paradox

In immunology, the "stickiness" or affinity of an antibody is traditionally viewed as the primary determinant of its neutralization potency. However, empirical data often show a poor correlation between these two metrics. This discrepancy suggests that monovalent binding parameters—typically measured in well-mixed laboratory environments—fail to capture the spatial complexities of viral surfaces. The key missing factor is bivalency: the ability of an antibody to use both arms (Fabs) to bind antigens simultaneously, creating a "double-grip" that is significantly stronger than a single-arm bond.

Methods: A Spatially Aware Particle-Based Model

To address the lack of a mechanistic way to measure the spatial limits of bivalent binding, researchers developed a stochastic, spatially resolved particle-based model using the Gillespie algorithm. Unlike standard Ordinary Differential Equation (ODE) models that assume a "well-mixed" state where any antigen on a surface is reachable, this new approach explicitly accounts for the physical distance between antigens and the geometric constraints of the antibody.

Schematic representation of bivalent binding transitions and the concept of reach. Standard models often assume an 'unlimited reach' where any antigen on a surface is accessible to the second antibody arm, whereas the new particle-based model introduces spatial constraints.

The model was applied to Surface Plasmon Resonance (SPR) data from over 45 patient-isolated IgG1 antibodies targeting the SARS-CoV-2 Receptor Binding Domain (RBD). By fitting the binding curves, the team extracted a new biophysical parameter: molecular reach—defined as the maximum distance an antibody can stretch to achieve bivalent binding.

Key Results: Reach as a Primary Predictor of Potency

The study found that molecular reach varies significantly across antibodies, ranging from 22 to 46 nm. Notably, these values often exceed the physical size of an IgG antibody (~15 nm). This phenomenon is attributed to the flexibility and size of the antigens themselves (such as the SARS-CoV-2 Spike), which effectively "lean in" to facilitate the bivalent bridge.

Quantification of molecular reach and secondary binding rates using the particle-based model. The particle-based bivalent model allows for the extraction of reach (nm) and the secondary binding rate ($k_{on,b}$), providing a more accurate fit than monovalent or standard ODE bivalent models.

Crucially, molecular reach proved to be a far superior predictor of viral neutralization than monovalent affinity. While affinity correlated weakly with neutralization ($R^2 \approx 0.31$), molecular reach showed a much stronger correlation ($R^2 \approx 0.52$). When combined with epitope location data, the predictive power reached an $R^2$ of 0.81. This explains why two antibodies with identical affinities for the same epitope can have vastly different potencies: the antibody with the longer reach can more effectively achieve bivalent binding on the sparse landscape of a viral spike. Furthermore, the model correctly predicted that bivalent binding only "kicks in" once antigen density reaches a threshold matching the antibody's reach, a condition precisely met by the SARS-CoV-2 virion.

Discussion and Implications

The identification of molecular reach as a critical determinant of neutralization has significant implications for vaccine and therapeutic design. Interestingly, the researchers found that switching antibody isotypes (e.g., from IgG to IgA) did not significantly alter the molecular reach, suggesting that this property is primarily determined by the specific Fab-hinge-Fc geometry. Future work will explore whether this principle holds for other viruses with different spike geometries, such as Influenza or HIV, and how these insights can be used to design vaccines that specifically favor antibodies with optimal reaches.

Summary updated

Abstract

Key functions of antibodies, such as viral neutralisation, depend on high-affinity binding. However, viral neutralisation poorly correlates with antigen affinity for reasons that have been unclear. Here, we use a new mechanistic model of bivalent binding to study >45 patient-isolated IgG1 antibodies interacting with SARS-CoV-2 RBD surfaces. The model provides the standard monovalent affinity/kinetics and new bivalent parameters, including the molecular reach: the maximum antigen separation enabling bivalent binding. We find large variations in these parameters across antibodies, including reach variations (22-46 nm) that exceed the physical antibody size (~15 nm). By using antigens of different physical sizes, we show that these large molecular reaches are the result of both the antibody and antigen sizes. Although viral neutralisation correlates poorly with affinity, a striking correlation is observed with molecular reach. Indeed, the molecular reach explains differences in neutralisation for antibodies binding with the same affinity to the same RBD-epitope. Thus, antibodies within an isotype class binding the same antigen can display differences in molecular reach, substantially modulating their binding and functional properties.
BibTeX
@inproceedings{huhn2025molecular,
  author = {Anna Huhn and Daniel A. Nissley and Daniel B. Wilson and Mikhail A. Kutuzov and Robert F. Donat and Tiong Kit Tan and Ying Zhang and Michael I. Barton and Chang Liu and Wanwisa Dejnirattisai and Piyada Supasa and Juthathip Mongkolsapaya and Alain Townsend and William James and Gavin Screaton and P. Anton van der Merwe and Charlotte M. Deane and Samuel A. Isaacson and Omer Dushek},
  title = {{The molecular reach of antibodies crucially underpins their viral neutralisation capacity}},
  booktitle = {Nature Communications},
  year = {2025},
  doi = {10.1038/s41467-024-54916-5},
}
Figure